News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
747,028 Results
Type
Article (45943)
Company Profile (670)
Press Release (700410)
Multimedia
Podcasts (190)
Webinars (31)
Section
Business (211849)
Career Advice (2716)
Deals (37249)
Drug Delivery (166)
Drug Development (82830)
Employer Resources (179)
FDA (16737)
Job Trends (15913)
News (357010)
Policy (32736)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (4)
2027 Genetown Standard (6)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (6)
Academia (2214)
Academic (2)
Accelerated approval (56)
ADA (49)
Adcomms (34)
Allergies (204)
Alliances (51997)
ALS (237)
Alzheimer's disease (1898)
Antibody-drug conjugate (ADC) (560)
Approvals (17175)
Artificial intelligence (807)
ASCO (333)
Autoimmune disease (369)
Automation (63)
Bankruptcy (387)
Best Places to Work (11770)
BIO (72)
BIOSECURE Act (23)
Biosimilars (242)
Biotechnology (417)
Bladder cancer (200)
Brain cancer (78)
Breast cancer (813)
Cancer (6461)
Cardiovascular disease (542)
Career advice (2313)
Career pathing (50)
CAR-T (374)
CDC (50)
Celiac Disease (2)
Cell therapy (1038)
Cervical cancer (57)
Clinical research (72501)
Collaboration (2373)
Commercialization (1)
Company closure (8)
Compensation (1512)
Complete response letters (104)
COVID-19 (2761)
CRISPR (121)
C-suite (1306)
Cystic fibrosis (164)
Data (8722)
Decentralized trials (3)
Denatured (59)
Depression (188)
Dermatology (93)
Diabetes (687)
Diagnostics (7286)
Digital health (68)
Diversity (10)
Diversity, equity & inclusion (43)
Drug discovery (397)
Drug pricing (232)
Drug shortages (36)
Duchenne muscular dystrophy (317)
Earnings (93534)
Editorial (77)
Employer branding (24)
Employer resources (160)
Events (125906)
Executive appointments (1187)
FDA (20822)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (21)
Frontotemporal dementia (35)
Funding (1926)
Gene editing (267)
Generative AI (77)
Gene therapy (825)
GLP-1 (1258)
Government (4283)
Grass and pollen (8)
Guidances (417)
Healthcare (18737)
Hematology (191)
HIV (97)
Huntington's disease (67)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (115)
Immunology and inflammation (345)
Immuno-oncology (114)
Indications (220)
Infectious disease (3140)
Inflammatory bowel disease (239)
Inflation Reduction Act (15)
Influenza (145)
Intellectual property (326)
Interviews (528)
IPO (17495)
IRA (55)
Job creations (4493)
Job search strategy (1872)
JPM (68)
Kidney cancer (21)
Labor market (109)
Layoffs (675)
Leadership (49)
Legal (8236)
Liver cancer (105)
Longevity (35)
Lung cancer (852)
Lymphoma (474)
Machine learning (67)
Management (63)
Manufacturing (1227)
Marketing (4)
MASH (226)
Medical affairs (1)
Medical device (14659)
Medtech (14838)
Mergers & acquisitions (21073)
Metabolic disorders (1799)
mRNA (258)
Multiple sclerosis (203)
NASH (21)
Neurodegenerative disease (510)
Neuropsychiatric disorders (124)
Neuroscience (3628)
Neurotech (1)
NextGen: Class of 2026 (6784)
Non-profit (3825)
Now hiring (83)
Obesity (866)
Opinion (362)
Ovarian cancer (242)
Pain (277)
Pancreatic cancer (367)
Parkinson's disease (411)
Partnered (38)
Patents (662)
Patient recruitment (795)
Peanut (72)
People (62565)
Pharmaceutical (114)
Pharmacy benefit managers (35)
Phase 1 (22624)
Phase 2 (32029)
Phase 3 (24028)
Pipeline (9991)
Policy (353)
Postmarket research (2437)
Preclinical (9487)
Press Release (66)
Prostate cancer (342)
Psychedelics (67)
Radiopharmaceuticals (368)
Rare diseases (1264)
Real estate (6238)
Recruiting (77)
Regulatory (26199)
Reports (51)
Research institute (2134)
Resumes & cover letters (421)
Rett syndrome (45)
RNA editing (29)
RSV (93)
Schizophrenia (193)
Series A (342)
Series B (246)
Service/supplier (24)
Sickle cell disease (127)
Special edition (31)
Spinal muscular atrophy (173)
Sponsored (45)
Startups (4042)
State (2)
Stomach cancer (21)
Supply chain (144)
Tariffs (101)
The Weekly (128)
Vaccines (1209)
Venture capital (135)
Weight loss (589)
Women's health (138)
Worklife (25)
Date
Today (126)
Last 7 days (515)
Last 30 days (2589)
Last 365 days (31900)
2026 (16889)
2025 (31674)
2024 (36681)
2023 (41457)
2022 (52106)
2021 (56086)
2020 (54101)
2019 (46686)
2018 (35526)
2017 (34216)
2016 (33343)
2015 (38982)
2014 (32405)
2013 (27736)
2012 (29038)
2011 (29045)
2010 (27057)
Location
Africa (882)
Alabama (101)
Alaska (6)
Arizona (324)
Arkansas (14)
Asia (44939)
Australia (7442)
California (14362)
Canada (4007)
China (1594)
Colorado (615)
Connecticut (638)
Delaware (441)
Europe (100667)
Florida (2128)
Georgia (454)
Hawaii (4)
Idaho (64)
Illinois (1158)
India (105)
Indiana (665)
Iowa (27)
Japan (603)
Kansas (134)
Kentucky (53)
Louisiana (58)
Maine (84)
Maryland (1621)
Massachusetts (10509)
Michigan (413)
Minnesota (793)
Mississippi (7)
Missouri (157)
Montana (36)
Nebraska (28)
Nevada (152)
New Hampshire (88)
New Jersey (3805)
New Mexico (34)
New York (3737)
North Carolina (1897)
North Dakota (11)
Northern California (7229)
Ohio (430)
Oklahoma (27)
Oregon (51)
Pennsylvania (2806)
Puerto Rico (33)
Rhode Island (55)
South America (1261)
South Carolina (86)
South Dakota (1)
Southern California (5612)
Tennessee (224)
Texas (2285)
United States (50755)
Utah (412)
Vermont (2)
Virginia (363)
Washington D.C. (83)
Washington State (1167)
West Virginia (4)
Wisconsin (150)
Wyoming (2)
747,028 Results for "eli lilly and company".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.
April 1, 2026
·
3 min read
·
Heather McKenzie
Obesity
Lilly’s tirzepatide will be biggest blockbuster ever, topping $70B by 2032: Evaluate
Eli Lilly’s weight-loss franchise—including the tirzepatide products Mounjaro and Zepbound, and the weight-loss pill Foundayo—is projected to account for nearly half of the total sales of the top 10 drugs in 2032.
June 23, 2026
·
2 min read
·
Tristan Manalac
Vaccines
Lilly just bought renowned regulator Peter Marks a pipeline to play with
FDA veteran Peter Marks will now shape the future of Eli Lilly’s vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.
May 27, 2026
·
2 min read
·
Annalee Armstrong
Cancer
ASCO: A battle of bispecifics, Eli Lilly’s big win and more
Practice-changing data in lung cancer, prostate cancer and more were on display over the weekend at the American Society of Clinical Oncology annual meeting in Chicago. Plus, early readouts on assets that could reshape the cancer landscape.
June 1, 2026
·
4 min read
·
Brianna Abbott
Alzheimer’s disease
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month course of Lilly’s product.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Gene editing
Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study
A single 1-mg/kg dose of Eli Lilly’s base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia. The pharma acquired the asset last year in the $1.3 billion Verve Therapeutics buy.
May 26, 2026
·
2 min read
·
Tristan Manalac
Neuroscience
Lilly bets up to $800M for BioArctic’s brain delivery tech
Eli Lilly plans to use BioArctic’s technology to shuttle an undisclosed drug candidate into the brain. The pharma hasn’t specified which neurodegenerative disease it will target.
June 22, 2026
·
2 min read
·
Tristan Manalac
Cancer
Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy
Eli Lilly’s new JAK2 inhibitor—which it obtained from the recent acquisition of Ajax Therapeutics—reduced spleen volume by more than a third in 70% of patients with myelofibrosis.
June 15, 2026
·
2 min read
·
Tristan Manalac
Bankruptcy
Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy
As Sangamo runs out of cash, Eli Lilly and Astellas have emerged as stalking horse bidders for key assets, including a Fabry gene therapy currently being submitted for potential FDA approval.
June 23, 2026
·
3 min read
·
Gabrielle Masson
Mergers & acquisitions
Lilly’s $25B+ M&A spree captures half of pharma’s 2026 capacity
Over the past decade, Eli Lilly has bought out more biotechs than any of the other top 12 pharmas by revenue—with 10 of those acquisitions arriving just this year.
June 10, 2026
·
1 min read
·
Annalee Armstrong
1 of 74,703
Next
